| Literature DB >> 34017594 |
Brian M Pecson1, Emily Darby1, Charles N Haas2, Yamrot M Amha3, Mitchel Bartolo4, Richard Danielson5, Yeggie Dearborn5, George Di Giovanni6, Christobel Ferguson7, Stephanie Fevig7, Erica Gaddis8, Donald Gray9, George Lukasik10, Bonnie Mull10, Liana Olivas3, Adam Olivieri11, Yan Qu3.
Abstract
In response to COVID-19, the international water community rapidly developed methods to quantify the SARS-CoV-2 genetic signal in untreated wastewater. Wastewater surveillance using such methods has the potential to complement clinical testing in assessing community health. This interlaboratory assessment evaluated the reproducibility and sensitivity of 36 standard operating procedures (SOPs), divided into eight method groups based on sample concentration approach and whether solids were removed. Two raw wastewater samples were collected in August 2020, amended with a matrix spike (betacoronavirus OC43), and distributed to 32 laboratories across the U.S. Replicate samples analyzed in accordance with the project's quality assurance plan showed high reproducibility across the 36 SOPs: 80% of the recovery-corrected results fell within a band of ±1.15 log10 genome copies per L with higher reproducibility observed within a single SOP (standard deviation of 0.13 log10). The inclusion of a solids removal step and the selection of a concentration method did not show a clear, systematic impact on the recovery-corrected results. Other methodological variations (e.g., pasteurization, primer set selection, and use of RT-qPCR or RT-dPCR platforms) generally resulted in small differences compared to other sources of variability. These findings suggest that a variety of methods are capable of producing reproducible results, though the same SOP or laboratory should be selected to track SARS-CoV-2 trends at a given facility. The methods showed a 7 log10 range of recovery efficiency and limit of detection highlighting the importance of recovery correction and the need to consider method sensitivity when selecting methods for wastewater surveillance.Entities:
Year: 2021 PMID: 34017594 PMCID: PMC8129921 DOI: 10.1039/d0ew00946f
Source DB: PubMed Journal: Environ Sci (Camb) ISSN: 2053-1400 Impact factor: 4.251
Participating laboratories
| Lab name | Lab type | State |
|---|---|---|
| Biological Consulting Services (BCS) Laboratories | Commercial | FL |
| Cel Analytical | Commercial | CA |
| City of Scottsdale | Government | AZ |
| City University of New York | Academic | NY |
| Columbia University | Academic | NY |
| Hampton Roads Sanitation District | Utility | VA |
| IDEXX Laboratories, Inc. | Manufacturer | ME |
| Los Angeles County Sanitation Districts | Utility | CA |
| Michigan State University | Academic | MI |
| Mycometrics | Commercial | NJ |
| New York City Department of Environmental Protection | Government | NY |
| Ohio State University | Academic | OH |
| Oregon State University | Academic | OR |
| Promega Corporation | Manufacturer | WI |
| Saginaw Valley State University | Academic | MI |
| SiREM | Commercial | TN |
| Source Molecular Corporation | Commercial | FL |
| Southern Nevada Water Authority | Utility | NV |
| Tulane University | Academic | LA |
| United States Environmental Protection Agency | Government | OH |
| University of California – Berkeley | Academic | CA |
| University of California – Irvine | Academic | CA |
| University of Colorado – Boulder | Academic | CO |
| University of Maryland | Academic | MD |
| University of Missouri | Academic | MO |
| University of Nebraska | Academic | NE |
| University of Nebraska – Medical Center | Academic | NE |
| University of Utah | Academic | UT |
| University of Wisconsin | Academic | WI |
| Utah State University | Academic | UT |
| Weck Labs | Commercial | CA |
| Wisconsin State Lab of Hygiene | Government | WI |
WWTP flows and water quality
| Parameter | Plant 1 | Plant 2 |
|---|---|---|
| Annual average flow (MGD) | 275 | 260 |
| Total suspended solids (mg L−1)[ | 420 (±60) | 520 (±40) |
| pH[ | 7.5 (±0.2) | 6.9 (±0.1) |
| Temperature (°C)[ | 30 (±1) | 38 (±1) |
Averages (plus/minus standard deviation) are based on the sample aliquots collected on the sampling day.
Key method steps and categorization of the SOPs
| Method group | SOP | Sample volume (mL) | Pre-treatment | Concentration step | Extraction | Molecular analysis[ | Concentration factor | ||
|---|---|---|---|---|---|---|---|---|---|
| Pasteurization | Solids removal | Chemical addition | |||||||
| 1 | 1.1 | 0.25 | No | None[ | None or RNA shield | None | Zymo Quick-RNA Fecal/Soil Microbe Microprep kit | Q | 17 |
| 1.2(H) | 40 | Half the samples | PureYield Plasmid Midiprep system | Q | 500 | ||||
| 1.3 | 45 | No | Qiagen RNeasy PowerSoil Total RNA kit | Q | 450 | ||||
| 1S | 1S.1(H) | 40 | Half the samples | Yes ( | None or salt addition ( | PureYield Plasmid Midiprep system | Q | 500 | |
| 1S.2H | 40 | All samples | Zymo III-P silica column | Q | 200 | ||||
| 1S.3(H) | 2 | Half the samples | Qiagen QIAamp Viral RNA mini kit | D | 5 | ||||
| 2 | 2.1 | 30 | No | None[ | Beef extract or phosphate buffered saline (PBS) | Zymo Quick-DNA/RNA Viral kit | Q | 60 | |
| 2.2 | 30 | No | Zymo Quick-DNA/RNA Viral kit | Q | 60 | ||||
| 2.3 | 225 | No | Qiagen AllPrep PowerViral kit and Qiagen RNeasy PowerWater kit | D | 1800 | ||||
| 2S | 2S.1 | 50 | No | Yes ( | None | Ultrafiltration[ | Qiagen RNeasy mini kit | Q | 40–200 |
| 2S.2 | 105 | No | IDEXX Water DNA/RNA Magnetic Bead kit | Q | 380–980 | ||||
| 2S.3 | 150 | No | Invitrogen PureLink Viral RNA/DNA mini kit | Q | 220–630 | ||||
| 2S.4(H) | 50 | Half the samples | Agilent Absolutely RNA Miniprep kit | Q | 500 | ||||
| 2S.5 | 25 | No | TRIzol | Q | 63–280 | ||||
| 2S.6 | 30 | No | Zymo Quick-RNA Miniprep kit | Q | 16–18 | ||||
| 3 | 3.1 | 50 | No | None | Acid (HCl) to lower pH and (optionally) addition of salt ( | HA filtration[ | NUCLISENS easyMAG | D | 250 |
| 3.2 | 100 | No | Qiagen QIAamp Viral RNA kit | Q | 880–2100 | ||||
| 3.3 | 50 | No | Qiagen AllPrep PowerViral DNA/RNA kit | Q | 280–470 | ||||
| 3.4 | 25 | No | Qiagen RNeasy PowerMicrobiome kit using PowerBead tubes | D | 420 | ||||
| 3.5 | 40 | No | Qiagen RNeasy PowerMicrobiome kit using BashingBead tubes | Q | 40–200 | ||||
| 3.6 | 30 | No | Applied Biosystems MagMAX Viral/Pathogen Nucleic Acid Isolation kit | D | 200–230 | ||||
| 3S | 3S.1 | 200 | No | Yes ( | Acid (HCl) to lower pH after solids removal | Qiagen AllPrep PowerViral DNA/RNA kit | Q | 2000 | |
| 3S.2H | 100 | All samples | Phenol extraction | Q | 380–1300 | ||||
| 3S.3H | 50 | All samples | Phenol extraction | Q | 160–510 | ||||
| 4 | 4.1 | 100 | No | None | Salt (NaCl) and PEG | Qiagen QIAamp Viral RNA kit | D | 60–96 | |
| 4.2 | 100 | No | Qiagen QIAamp Viral RNA kit | D | 53 | ||||
| 4.3 | 100 | No | Qiagen QIAamp Viral RNA kit | D | 55–83 | ||||
| 4.4 | 282 | No | Qiagen QIAamp Viral RNA kit | Q | 220 | ||||
| 4S | 4S.1(H) | 40 | Half the samples | Yes ( | Salt (NaCl) and PEG after solids removal | PEG precipitation | TRIzol | Q | 850–1300 |
| 4S.2(H) | 105 | Half the samples | IDEXX Water DNA/RNA Magnetic Bead kit | Q | 530 | ||||
| 4S.3 | 45 | No | Qiagen RNeasy PowerMicrobiome kit using PowerBead tubes | D | 130 | ||||
| 4S.4 | 36 | No | Qiagen QIAamp Viral RNA kit | Q | 590 | ||||
| 4S.5H | 40 | All samples | Qiagen AllPrep PowerViral DNA/RNA kit | Q | 670 | ||||
| 4S.6(H) | 200 | Half the samples | NucleoMag Pathogen RNA Isolation kit | Q | 170 | ||||
| 4S.7 | 40 | No | Invitrogen PureLink Viral RNA/DNA mini kit | Q | 34–170 | ||||
| 4S.8(H) | 400 | Half the samples | Qiagen QIAamp Viral RNA kit | D | 470 | ||||
SOP 1.3 centrifuged sample and analyzed solids.
SOP 2.3 separated solids and analyzed both solid and liquid fractions.
SOP 2S.5 used a concentrating pipette tip in the concentration step (similar principle to ultrafilter).
SOP 3S.1 filters the sample through an electropositive filter to remove solids and then elutes the viruses adsorbed to the filter with beef extract. The eluant is further concentrated with organic flocculation and ultrafiltration before extraction.
“Q” indicates reverse transcription quantitative PCR and “D” indicates reverse transcription digital PCR.
Primer and probe sequences for SARS-CoV-2 (N1 and N2 targets) and OC43
| Target | Primer/probe sequences | Ref. |
|---|---|---|
| SARS-CoV-2 N1 | F: 5’-GAC CCC AAA ATC AGC GAA AT-3’ | 2019-nCoV CDC EUA kit, IDT Catalog No. 10006606 |
| SARS-CoV-2 N2 | F: 5’-TTA CAA ACA TTG GCC GCA AA-3’ | 2019-nCoV CDC EUA kit, IDT Catalog No. 10006606 |
| OC43 | F: 5’-CGATGAGGCTATTCCGACTAGGT-3’ | Dare, R.K. |
Quality control rationale for exclusion of SOPs
| SOPs excluded from method analysis | Quality control rationale |
|---|---|
| 1S.1 (H) | Processed more than 24 h outside specified window |
| 3.2 (excluded N1 results only) | Positives in N1 NTC |
| 2S.1 (still included in method sensitivity analysis) | Low recovery (<0.01%) |
| 3S.1 (still included in method sensitivity analysis) | Low recovery (<0.01%) |
Two thirds of SOPs had at least one molecular replicate that were marked as non-detect due to the results falling outside of the range covered by the standard curve. NDs were not included in the analysis of SARS-CoV-2 results, but the SOPs were still included in method sensitivity analysis.
Fig. 1Recovery-corrected SARS-CoV-2 concentrations (N1 and N2 targets) at Plant 1 measured by each SOP. NDs and data excluded based on the quality control criteria are not plotted. The dashed lines show 10th and 90th percentiles across all N1 and N2 results.
Fig. 2Log-transformed OC43 recovery efficiency at Plant 1 (Hyperion) and Plant 2 (JWPCP), measured by each SOP. The SARS-CoV-2 results from the SOPs highlighted are not represented in Fig. 1 due to the fact that the results were all non-detect (gray), the recovery was below the quality control cut-off of 0.01% (blue), or both (orange).
Fig. 3Comparison of the log-transformed SARS-CoV-2 (N1) concentrations at Plant 1 measured by each of the eight method groups (grouped by concentration step and solids removal). The number of SOPs and total sample replicates included in each method group are shown at the top of the box plot.
Median and range of standard deviations for sample replicates processed by the same SOP
| Target | Uncorrected | Recovery-corrected |
|---|---|---|
| N1 | 0.15 [0.04–0.38] | 0.13 [0.032–0.60] |
| N2 | 0.14 [0.01–0.53] | 0.13 [0.033–0.51] |
Fig. 4Log-transformed theoretical limits of detection for each SOP at Plant 1 (Hyperion) and Plant 2 (JWPCP). The dashed lines show 10th and 90th percentiles across both Plant 1 and Plant 2. The total number of non-detects (ND) (combined for SARS-CoV-2 N1 and N2 targets) out of total number of sample replicates processed by each SOP is shown in the table below the box plot (a blank cell indicates no NDs). An “X” indicates the sample was not processed by that SOP.
Fig. 5Fraction of sample replicates that were non-detect at Plant 1 as a function of the theoretical LOD. The outlier shown in gray (SOP 3S.1) processed the sample using a different PCR platform to enumerate OC43 and SARS-CoV-2.
Fig. 6Comparison of the log-transformed theoretical limits of detection (combined for Plant 1 and Plant 2) for each of the eight method groups (grouped by concentration step and solids removal).
Fig. 7Impact of heat pasteurization on the log-transformed SARS-CoV-2 (N1 target) concentrations (corrected for recovery efficiency) at Plant 1. Five sample replicates for each SOP, with and without heat pasteurization, were performed.
Fig. 8Impact of the PCR platform (digital or quantitative) on the log-transformed SARS-CoV-2 (N1 target) concentrations (corrected for recovery efficiency) at Plant 1. The data are from 22 SOPs (93 replicates) that used quantitative PCR and 8 SOPS (39 replicates) that used digital PCR.
Fig. 9.Impact of the surrogate used for the matrix spike on the log-transformed recovery efficiency at Plant 1. Five sample replicates for each SOP were processed and analyzed for both OC43 and the second matrix spike surrogate.